GSK plc (GSK) vs Roivant Sciences Ltd. (ROIV)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| GSK | ROIV | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Size band | LARGE | LARGE |
| Listing | NYSE | Nasdaq GS |
| Country | United Kingdom | United Kingdom |
| Theme | pharmaceuticals-large-cap | rare-disease |
| Price and returns | ||
| Last close | $51.10 | $36.05 |
| Return · 1 week | +3.32% | +3.89% |
| Return · 1 month | +2.82% | −2.51% |
| Return · 3 months | −4.86% | +6.53% |
| Return · year to date | +4.74% | +64.39% |
| Return · 1 year | +19.72% | +91.65% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −17.18% | −15.18% |
| 52-week high | $61.70 | $42.50 |
| 52-week low | $42.85 | $17.54 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $101.68B | $26.04B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $158.70M | $222.91M |
| Employees | 66,841 | 721 |
| Valuation | ||
| Price to earnings · trailing | 15.62× | n/a (negative earnings) |
| Price to earnings · forward | 10.06× | n/a (negative forward earnings) |
| Price to sales | 2.99× | 3215.55× |
| Price to book | 4.22× | 5.73× |
| Enterprise value to EBITDA | 10.53× | n/a (negative EBITDA) |
| Enterprise value to revenue | 3.43× | 2811.36× |
| PEG ratio | 6.03 | — |
| Earnings per share · trailing | 3.17 | -0.51 |
| Profitability | ||
| Gross margin | 72.73% | 81.21% |
| Operating margin | 30.94% | −25408.11% |
| Profit margin | 14.52% | −3534.96% |
| Return on equity | 33.38% | −8.52% |
| Return on assets | 10.01% | −16.48% |
| Growth | ||
| Revenue growth | +5.30% | −33.50% |
| Earnings growth | −69.50% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 106.50 | 2.18 |
| Current ratio | 0.82 | 16.72 |
| Dividend yield | 3.67% | 0.00% |
| Payout ratio | 56.55% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 61.33 | 58.65 |
| ADX · 14 | 22.21 | 17.87 |
| 50-day average | $49.60 | $36.64 |
| 200-day average | $52.36 | $31.07 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.07% | 3.93% |
The full GSK analysis
Everything this table leaves out for GSK plc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GSK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GSK analysisThe full ROIV analysis
Everything this table leaves out for Roivant Sciences Ltd.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ROIV argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ROIV analysis